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Alcohol Matrix cell A3: Interventions; Medical treatment
S  Handing patients  responsibi l i ty matches  extended treatment plus  medications  (1977). Describes  mould-breaking study in
London which found a brief sess ion handing responsibi l i ty to the couple to cure the husband’s  a lcohol ism worked as  wel l  as
extended treatment, which general ly involved medications. See also this  retrospective (2015) from a study researcher. Simi lar
Scottish study later found (1988) more evidence for extended treatment. Discussed in bi te’s  Where should I start? section.
S  Disul fi ram only works  with compl iant patients  (1986). Explains  that despite overal l  negative findings , the fi rst rigorous  tria l  of
the drug which causes  deterrent phys ical  reactions  after drinking found that some older and more socia l ly stable disul fi ram
patients  who completed the study did drink less  frequently after laps ing. Later the study was seen as  confi rming the need to
supervise the drug’s  administration to ensure more patients  took more of the pi l l s . Discuss ion in bi te’s  Issues section.
S  Impress ive results  from fi rst cl inical  tria l  of acamprosate (1985). Three months  later the success  rate among alcohol-dependent
patients  detoxi fied and discharged from a French inpatient unit was  61% i f they had been randomly a l located to acamprosate
versus  32% on placebo. It was  a  notable result among severely dependent patients  with a  record of fa i led treatments .
S  Benzodiazepines  best withdrawal  treatment (1969). Study which clari fied the dangerous  confus ion over how to prevent the l i fe-
threatening compl ications  of a lcohol  withdrawal .
K  Acamprosate unsuitable for some UK patients  (2000). Despite pos itive findings  elsewhere, large UK tria l  found acamprosate did
not curb relapse among detoxi fied alcohol ics . The findings  highl ighted the importance of an accompanying support programme to
help keep patients  in treatment and taking the pi l l s , and also perhaps  the type of patients  – steady drinkers  rather than the study’s
‘bingers ’ – who respond best to the treatment. Discuss ion in bi te’s  Highlighted study section.
K  Supervised disul fi ram works  in Bri ta in (1992). In the major UK tria l , disul fi ram s igni ficantly reduced drinking relative to a
vitamin pi l l  placebo by nearly 10 UK units  a  day. The researchers  thought their results  showed the importance of supervis ing
consumption and making patients  aware of the potentia l  consequences  of drinking whi le taking disul fi ram. Discuss ion in bi te’s
Highlighted study section.
K  Naltrexone can’t work unless  patients  take the pi l l s  (2000). In conditions  typical  of Bri tish a lcohol  treatment cl inics , when taken
as  directed naltrexone reduced post-detoxi fication drinking – but nearly 60% of patients  randomly a l located to naltrexone versus  a
placebo left treatment early and stopped taking the pi l l s . Discuss ion in bi te’s  Highlighted study section.
K  Naltrexone boosts  primary care treatment (2006). Within the same tria l , the large US ‘COMBINE’ study tested acamprosate,
naltrexone, and both together against a  placebo, and whether adding psychological  therapy boosted results  from medical  care.
Therapy elevated placebo drinking outcomes to match the most effective medications; without therapy, naltrexone elevated
outcomes to about the same degree. Results  supported prescribing naltrexone in primary care-based treatment with relatively
compl iant patients . Discuss ion in bi te’s  Issues section.
R  The power of the placebo (2013). Across  relevant tria ls , end-of-treatment improvements  in a lcohol  patients  randomly a l located
to an inactive placebo on average dwarfed estimates  (  reviews below) of additional  benefi ts  due to the pi l l  being an active
medication. Discuss ion in bi te’s  Issues section.
R  Evidence strongest for acamprosate and oral  naltrexone (2014). Amalgamates  findings  from 123 tria ls  of the ful l  range of
medications  prescribed for at least 12 weeks. Evidence was strongest for acamprosate and oral  naltrexone; each prevented 1
patient in 12 or 20 respectively returning to drinking. Naltrexone also prevented 1 in 12 returning to heavy drinking. Health
improvements  remained unclear. The few head-to-head comparisons  yielded no s igni ficant di fferences  between the two
medications  but other reviews amalgamating al l  relevant data have found minor di fferences.
R  Prescribing in primary care and general  medicine (2011). Based on studies  offering minimal  psychosocial  support, recommends
oral  naltrexone, topiramate or (with abstinent patients) acamprosate – and given supervised consumption and motivated,
abstinent patients , a lso disul fi ram. Medication should be accompanied by brief support to promote compl iance with treatment.
Even when l i ttle other support was  provided, improvements  due to medication were “modest”.
R  Who benefi ts  most from naltrexone versus  acamprosate? (2013). Amalgamated findings  from randomised tria ls  comparing the
two drugs  or (more often) comparing each to a  placebo indicated that on average naltrexone was best for patients  who want to
reduce heavy drinking, acamprosate for those seeking abstinence. A di fferent kind of analys is  (2014) confi rmed these conclus ions,
and another (2015) found no di fference in impacts  on drinking between European and (mainly) US caseloads. Al l  three reviews
found di fferences  s l ight as  were the effects  of each medication compared to placebo, and individual  tria ls  often fa i led to find
benefi ts .
R  Disul fi ram needs supervised consumption and patient awareness  (2014). Amalgamated research findings  indicate that
disul fi ram substantia l ly improves  on al ternatives  or placebo when (and on average, only when) compl iance is  bolstered by
supervis ing administration and patients  know they are taking a  drug which causes  unpleasant reactions  i f they drink. With the
careful  patient selection typical  of research tria ls , disul fi ram has  not been associated with excess  deaths  or serious  adverse
events . Di fferent kind of analys is  (2011) agreed that given wel l  supervised consumption, disul fi ram is  more effective than the
alternatives . Discuss ion in bi te’s  Issues section.
R  How to encourage patients  to take the pi l l s  (2004). Because the reasons  why alcohol  treatment patients  skip their medication are
varied, so too must be ways  to address  this , from reducing s ide-effects  and adjusting dose to compl iance-enhancing counsel l ing
and enrol l ing the fami ly. Discuss ion in bi te’s  Issues section.
R  Benzodiazepines  make withdrawal  safer and eas ier (2010). Rigorous  review and synthes is  of randomised tria ls  indicates  the
superiori ty of benzodiazepines  for control l ing the potentia l ly serious  medical  consequences  of withdrawing from dependent
drinking, especial ly seizures .
G  Officia l  Engl ish guidel ines  on treating harmful  drinking and alcohol  dependence (National  Insti tute for Health and Care
Excel lence, 2011). Bri ta in’s  gatekeeper to the publ ic provis ion of health care technologies  recommends cons idering acamprosate
or naltrexone after withdrawal , but relegates  disul fi ram to a  second-l ine option. Treatment and care should take into account the
patient’s  individual  needs  and preferences. Discuss ion of disul fi ram recommendations  in bi te’s  Issues section. See also Scottish
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primary care guidel ines.
G  Treating withdrawal  (Royal  Col lege of Phys icians, 2010). Guidance developed for Bri ta in’s  National  Insti tute for Health and Care
Excel lence on medical  care of patients  suffering acute withdrawal  from alcohol  or other a lcohol-related medical  conditions.
G  US consensus  cl inical  guidel ines  ([US] Substance Abuse and Mental  Health Services  Administration, 2009). From experts
convened by the US health department, how US-approved medications  (acamprosate, oral  and injectable naltrexone, and
disul fi ram) can be incorporated in to medical  practice, including choosing suitable patients .
G  Treating substance use service cl ients  with mental  health problems ([Austral ian] National  Drug and Alcohol  Research Centre,
2016). Funded by the Austral ian government; recommends services  screen al l  patients  for mental  health problems and that mental
i l lness  should not be a barrier to treating substance use problems. Research shows these patients  can benefi t as  much as  others
from routine treatments  for problem drinking.
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What is this cell about? About the treatment of alcohol dependence in a medical context and/or involving
medical care, typically by GPs or by alcohol treatment or psychiatric units in hospitals. Clinical staff are
res onsible for medications, so the centrality of these to an intervention distinguishes it most clearly as
medical. Drugs (primarily benzodiazepines) help patients withdraw from alcohol more comfortably and safely,
or (primarily in the UK acamprosate, but also naltrexone and disulfiram) are intended to sustain longer term
abstinence or moderate drinking.
But drugs are never all there is to medical care. They help to forge a relatively intoxication-free space during
which patients can lose the habit of regular drinking and be supported to find other ways to cope and construct
lives incompatible with a return to heavy drinking. Drug-based treatments also include potentially therapeutic
interactions with clinical and other staff, and ways to encourage patients to take medications. Sometimes this
means enlisting family and others, deepening their involvement in the patient’s recovery. Without these
factors there is a risk that any benefits of medication will be lost once the treatment ends.
Though usage has been increasing, in Britain treatment for alcohol dependence usually consists entirely of
advice and support. Drugs are almost universally used to ease withdrawal in inpatient units, but in 2013/14 in
England, of the 101,782 drinkers treated in non-residential community settings, just 16% were prescribed a
medication. As we’ll see later in this bite, relegation of medications to a minority option accurately reflects
their generally minor effects relative to the other influences which together constitute the ‘placebo effect’
seen in trials. For this ‘disease’, medications usually add little (but on average, do add a little) to the patient’s
impetus to get better, the processes in their life which help them realise and sustain this ambition, and the
impact of deciding to enter and get actively engaged in treatment, one manifestation of which is regularly
taking medication.
Where should I start? Exemplifying that last point, and helping place medication in context, is a seminal
study from England which questioned the orthodoxy that alcoholism requires intensive treatment. Griffith
Edwards and colleagues found that male alcoholics (accompanied by their wives) seen by a psychiatrist-led
team at an alcohol clinic did as well after a single brief session as after fully fledged treatment, which for
about two-thirds of patients included medications in the form of the disulfiram-like drug calcium cyanamide.
Looking back over nearly 40 years, a researcher on the study interpreted the results as meaning that formal
treatment had been less important than aspects of the process shared by both sets of couples: “all the
negotiations and arguments that must have gone on between husband and wife prior to and after the visit to
the [GP]; the referral to a psychiatric hospital and the wait for the appointment letter; the whole morning spent
going over one’s drinking and one’s marriage with a group of expert strangers; the unequivocal advice,
delivered in the presence of one’s spouse; ... knowing that the hospital was keeping a watching brief and that
questions were being asked about your behaviour every month and that you would be asked to account for
yourself at the year’s end.”
A similar study in Scotland included patients randomly allocated to just five minutes of advice or up to one
hour, as well as to extended treatment, which in this case rarely involved medications. Two years later 58% of
the extended treatment patients were abstinent or trouble-free drinkers compared to 39% of the advice
groups, a difference which verged on the statistically significant. It seemed to be largely due to significantly
greater reduction in alcohol-related problems rather than drinking itself, which was substantially reduced in
both advice and extended-treatment patients. For several reasons the advantage gained by extended
treatment was probably greater than the results suggest, but still the improvements in patients given the
briefest of interventions was considerable. Speculating on the causes, the researchers highlighted the
“unequivocal diagnosis and ... injunction to abstain” or “the decision of the patient to do something about his
drinking” – or both, since the “injunction” explicitly left their recovery up to the patient.
Highlighted study Jonathan Chick led the Scottish study summarised above and also our highlighted study.
Published in 1992, it remains the solidest UK foundation for prescribing disulfiram. Prescribing patients a
medication which causes very unpleasant reactions to alcohol seems a sure-fire deterrent to repeated
drinking, but this and other studies showed that even such powerful drugs are reliant on the patient’s
motivation and their social support – for disulfiram, especially the relatives and partners who with the
patient’s agreement help ensure the pills are taken. Even then, for many patients that will not be enough. The
highlighted study gave disulfiram the advantages of supervising consumption (usually done by husband or
wife) and the patients’ awareness that they were taking a deterrent drug, yet still nearly half (but no more so
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on disulfiram) effectively rejected or dropped out of treatment. Nevertheless, over the entire six-month follow-
up, disulfiram patients had reduced their drinking days and amounts drunk by significantly and substantially
more. In the final month – during which time many patients must have withdrawn from treatment – drinking
reductions remained apparent, but were no longer significant.
A striking finding was the huge difference in abstinence rates
between patients who largely complied with their treatments and
took the pills and those who were less compliant – even when
those pills were effectively an inactive placebo. Among the two
groups of patients given inactive pills, 50% and 43% of the minority
who largely took them were abstinent compared to 9% and 6% of
the remainder.
Another study from Dr Chick showed that the same applied to naltrexone, intended to moderate rather than
block drinking. With generally low social support and no supervised consumption, before the end of the 12
weeks during which naltrexone or placebo were prescribed nearly 60% of patients had terminated study and
treatment early. Despite this degree of loss, across all patients there remained signs that naltrexone had
reduced drinking, but the effects were not statistically significant. When the analysis was confined to patients
who had completed the study and had largely complied with treatment, there was still no evidence that
naltrexone had delayed a return to drinking, but the reduction in the amount subsequently drunk (on average
half that in the placebo group) was substantial and statistically significant, seemingly a sign that the
experience of drinking on naltrexone was not so ‘moreish’ as it had been without the drug. Dr Chick completed
the treble with his acamprosate study. Hampered by high drop-out and non-compliance rates – by the end of
the six-month trial fewer than 30% of patients were taking at least 90% of their tablets – it found no significant
reductions in drinking relative to a placebo.
Results of these three British studies emphasise measures to keep patients in treatment and taking their
medication. Well appreciated for disulfiram, the same applies to less absolutist medications like naltrexone
and acamprosate, which the British studies cited in this section suggest may also benefit from supervised
consumption. Not only does this help ensure pills are taken, but also more deeply involves family and
associates in the patient’s recovery. The next section addresses this issue directly.
Issues to consider and discuss
 If ‘compliance’ is crucial, how do we encourage patients to take the pills? No single or best
way, concluded a comprehensive review. A basic strategy stressed by UK guidelines is to build a trusting
relationship with patients and relate to them in a supportive, empathic and non-judgmental manner. Any
qualified practitioner can prescribe anti-drinking medications, but it takes particular skills and qualities to give
patients confidence in the treatment, encourage them to take the medication, and to maximise its effects.
Improving client-clinician relationships addresses some but not all of the reasons for non-compliance. Patients
may skip doses because of side-effects, because they do not feel they have a problem, don’t believe the
medication is doing any good, are overcome by cravings, simply forget, are disorganised (perhaps by
intoxication), or lack the right kind of support from family or associates – and so on!
Notice that some of these reasons may be ‘legitimate’ – and not just from the patient’s point of view. Side-
effects can be distressing or life-diminishing, conceivably some patients’ problems (drugs have been
recommended for non-dependent alcohol ‘abusers’) do not warrant taking side-effect producing pills several
times a day, and often medications do not help. Another reason to pause before taking strong measures to
increase pill-taking is that compliance may be a marker of a pre-existing good prognosis rather than a cause of
that prognosis. This is almost certainly part of the reason why even with an inactive placebo, good compliance
is associated with good outcomes – as in the major UK disulfiram trial  above. Good compliers tend to be
diligent, health-conscious and well-organised people, traits likely to facilitate recovery from any illness,
condition or misfortune. If this is the case, ‘artificially’ boosting compliance with an ineffective or only
minimally effective medication will not improve outcomes to the degree expected from how well naturally
good compliers do in research trials. On the other hand, even highly effective medications cannot exert their
effects unless they are taken.
Given these considerations, how far should we go to overcome resistance to regularly taking pills?
Inducements for complying, sanctions for not? As a last-ditch measure, criminal justice sanctions have been
tried with some success in Britain to persuade offenders otherwise facing several months in prison to take
disulfiram to reduce their alcohol-related offending. Loss of employment or professional status and ‘tough-
love’ pressure are other tactics. As long as the patient is free to refuse and does not suffer sanctions simply
for refusing, everyone can benefit: offenders avoid prison, prisons are relieved of some pressure, public money
is saved, doctors can practice, their patients benefit, employees can continue to contribute to their work and
society, and families are preserved.
Such benefits depend on how far medications really do protect patients and others from the serious
consequences of continued heavy drinking, and that in turn (especially for disulfiram) depends on patients
taking their medication. However, with naltrexone it is possible at least for a month or so to ensure the drug is
active and take patient choice out of the equation by irreversibly injecting a long-acting formulation of the
drug. It can help some patients cut down their drinking, as in this freely available pilot study. But in this trial,
at least a third of full-dose patients experienced side-effects and – not least – if they had needed opiate-
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based pain relief, it would have been blocked by the long-acting injection. Long-acting naltrexone is one of the
measures which by improving compliance also seems to have improved drinking outcomes relative to
naltrexone pills taken every day.
 Is disulfiram defunct? There was a time when it seemed to be going that way. In the mid-80s overall
negative results from the first rigorous trial led the researcher to expect prescribing to wither. That did not
happen in the USA and neither has it yet in Britain, where in England in 2015 disulfiram was dispensed 52,466
times. Though still a substantial player, the medication was on a downward trend from a peak of 60,842 in
2012 and well behind the 139,193 recorded for acamprosate in 2015. In hospitals as opposed to GPs’
surgeries, disulfiram used to be dispensed more often than acamprosate, but by 2013 that had reversed and by
2015, even in these specialist settings acamprosate was well ahead. One possibility is that lack of promotion
and research in respect of this older medication have let it slip in comparison with newer products. However,
in some British alcohol treatment units it has routinely and seemingly successfully been prescribed after
detoxification.
Those doctors and patients have support from reviews which found the drug more effective than other
medications, as long as consumption was supervised. One review was a particularly sophisticated analysis
which divided trials into those which did or did not supervise consumption, and in which patients as well as
researchers and doctors did not know whether they were taking disulfiram (‘double-blind’) versus those in
which patients knew they were taking a drug which would cause unpleasant reactions if they drank. The
results showed that the ‘gold standard’ double-blind methodology
robbed disulfiram of its main active ingredient – the expectation of a
nasty reaction if one returns to drinking – and that as well as this
knowledge, patients usually need someone to bolster their resolve by
making sure they take the pills. Given these circumstances, disulfiram
not only substantially bettered a placebo in reducing drinking at the
end of the treatment period but also substantially bettered naltrexone and acamprosate. Then take a look at
the other review and at our commentary on its findings. Note also that British trials have found disulfiram
effective but acamprosate not.
The drug’s modus operandi has been explained by experienced clinicians. First is the patient’s knowledge that
disulfiram will cause an unpleasant reaction after drinking. Secondly, “taking disulfiram ... has certain symbolic
connotations. It tells us that here is a patient who is willing ... to surrender some control over his freedom or
urge to drink. Such a patient announces both to himself and to the wider world that he is not merely talking
about changing his drinking habits ... but is actually doing something about it.” The final element derives from
the need for the drug’s administration to be supervised if more than a small minority of patients are to benefit,
providing “additional opportunities for involving family members in the broader therapeutic and monitoring
enterprise.” Disulfiram is uncompromising in its distinctive effects, yet even for this drug, social, cognitive and
symbolic influences mediate its impact on drinking.
With this information at your disposal, do you think the National Institute for Health and Care Excellence
(NICE), the UK’s authority on medical treatments, was right to say disulfiram should normally only be
considered when acamprosate or oral naltrexone are not suitable. Burrow through their report, and you will
see that apart from the risks, this was because the evidence was weaker than for other drugs, which in turn
was due to the lack of ‘double-blind’ trials – those in which neither patients nor research assessors know who
has taken what. Disulfiram’s reviewers dismissed this as a “meaningless” concern, because the main active
ingredient of the treatment is that patients know they have taken a drug which will cause a nasty reaction if
they drink.
After making your judgement you may find yourself agreeing with one or other side of a deep divide in
academic and expert opinion: one side sees disulfiram as a poorly evidenced and risky option best kept in
reserve; another advocates its routine use, arguing that though it needs careful monitoring and usually
supervised administration, among patients who will accept this option, it is safe and at least as effective as
other medications. Underlying these views can be found differences in understandings of alcohol dependence.
According to one view, the treatment merely suppresses drinking while disulfiram is being taken without
“target[ing] the core phenomenon of alcohol dependence”. Understanding dependent drinking as a learnt
reaction to certain cues, another view is that the treatment precisely targets that core by forcing a dislocation
between cues and drinking which with repetition can become cemented, underpinning the construction of an
alcohol-free way of living.
 The placebo effect is the main active ingredient Across randomised trials and across all
medications, these have only a modest impact on drinking relative to a pharmacologically inactive placebo.
This is generally also true of both acamprosate and naltrexone, though disulfiram is a partial exception; in the
special circumstances when doses can be and are effectively supervised to make sure pills are taken, effects
verge on what is conventionally considered large.
It means that most patients do almost or just as well if offered a placebo instead of these medications. We
can get a feel for how closely the placebo effect matches that of an active medication from an amalgamation
of research on naltrexone and acamprosate. It found that six months after treatment started, 65% of placebo
patients had lapsed to drinking compared to 77% prescribed acamprosate. Three months after treatment
started the corresponding figures for naltrexone were 65% and 71%, while for relapse to heavy drinking they
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were 50% versus 59%. In each case these raw figures amounted to a statistically significant advantage for the
medications, but a slight one which in individual trials often failed to materialise.
Usually research and reviews focus on the medication, but one revealing analysis has focused instead on the
placebos against which alcohol medications have been benchmarked. Across relevant trials, improvements in
alcohol patients randomly allocated to an inactive placebo on average dwarfed those analyses have found
attributable to the additional effects of an active medication. The more severe the dependence, the greater
was the improvement among placebo patients, and the greater that improvement, the less was gained by
prescribing an active medication.
Unusually, the large US COMBINE study directly tested the power of a placebo by including set of patients not
even prescribed an inactive pill, but instead allocated to what should have been a powerful psychosocial
therapy. Their abstinence record was significantly worse (67% v. 74% days abstinent) than patients allocated
to straightforward medical care but also prescribed a placebo – a testimony to the power of the placebo effect
either (as the authors speculated) in positive form as a response to being prescribed medication, or in
negative form as disappointment at not being prescribed. “Somewhat unexpectedly,” said the researchers,
“we observed a positive effect of receiving placebo medication and medical management over and above that
seen with specialist-delivered behavioural therapy alone.” Though large, placebo effects found in randomised
trials of this kind might be weakened because research participants are normally told they stand a 1 in 2
chance of being prescribed an inactive placebo, dampening expectations that the pills will work.
What the ‘placebo effect’ consists of has yet to be adequately unpacked, but it is almost certainly far more
than a reaction to taking a pill. Some of the apparent effect will be
natural remission, but the fact that the more often a placebo is
taken, the greater the reduction in drinking, suggests that the
social and psychological influences associated with being actively
engaged in treatment mediate much of the effects of medications.
The impact of engaging in a treatment understood in that culture to help ‘cure’ the condition is one the
‘common factors’ explored in cell A2’s bite – and in Western societies, taking a medicine is perhaps the prime
culturally endorsed way to signal the existence of a curable condition and to cure it. Another factor is how the
clinician relates to the patient, the possible effect of which emerged in the arm of US COMBINE alcohol
treatment trial which evaluated medical care allied with pharmacotherapy in the form of the doctor’s ability to
credibly convey optimism about recovery. More on relationship issues in cell B3.
These findings should come as no surprise. Across medicine, when a condition is susceptible to expectations
(such as depression and pain for example, but not the cancer which may be causing these) placebo effects
rival those of active medications, and do so partly because the context and the expectations of the patient
themselves induce biochemical effects which can mimic those of medications, including generation of the
body’s natural opiate-type chemicals.
Thanks for their comments on this entry to Colin Brewer of the Stapleford Centre in England and Duncan Raistrick, formerly of the Leeds
Addiction Unit in England and now Co-Director of RESULT. Commentators bear no responsibility for the text including the interpretations
and any remaining errors.
 Close Matrix Bite 
converted by Web2PDFConvert.com
